Protagenic Therapeutics, Inc.\new - FORM 10-K/A - EX-23.1 - EXHIBIT 23.1 - May 5, 2017

Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Protagenic Therapeutics, Inc.\newex99-1.htm
EX-32.1 - EXHIBIT 32.1 - Protagenic Therapeutics, Inc.\newex32-1.htm
EX-31.2 - EXHIBIT 31.2 - Protagenic Therapeutics, Inc.\newex31-2.htm
EX-14.3 - EXHIBIT 14.3 - Protagenic Therapeutics, Inc.\newex14-3.htm
EX-14.2 - EXHIBIT 14.2 - Protagenic Therapeutics, Inc.\newex14-2.htm
EX-14.1 - EXHIBIT 14.1 - Protagenic Therapeutics, Inc.\newex14-1.htm
EX-10.16 - EXHIBIT 10.16 - Protagenic Therapeutics, Inc.\newex10-16.htm
10-K/A - FORM 10-K/A - Protagenic Therapeutics, Inc.\newatrn20170503_10ka.htm

Exhibit 23.1 

 

 

Independent Registered Public Accounting Firm’s Consent

 

 

We consent to the incorporation by reference in this Registration Statement of Protagenic Therapeutics, Inc. on Forms S-8, [FILE NO. 333-214553 and 333-214554) of our report dated April ??, 2017, with respect to our audits of the consolidated financial statements of Protagenic Therapeutics, Inc. as of December 31, 2016 and 2015 and for the years then ended appearing in the Annual Report on Form 10-K of Protagenic Therapeutics, Inc. for the year ended December 31, 2016. We also consent to the reference to our firm under the heading “Experts” in the Prospectus, which is part of this Registration Statement.

 

 

/s/ Marcum llp

 

Marcum llp

New York, NY

April 17, 2017

Protagenic Therapeutics, Inc.\new Reports